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Objectives
To assess the presence of self-reactive immune responses to seminal and prostate antigens (PAg), biomarkers of
inflammation of the male genital tract, and semen quality parameters in patients with chronic prostatitis/chronic pelvic pain
syndrome (CP/CPPS).
Patients, Subjects and Methods
Peripheral blood and semen samples were collected from patients with CP/CPPS and age-matched healthy control
volunteers. We analysed the lymphoproliferative responses of peripheral blood mononuclear cells (PBMC) to different
seminal plasma (SP)-derived and purified PAg, serum autoantibodies specific to PAg, leucocyte subpopulations, and
inflammatory cytokines in semen, sperm apoptosis/necrosis, and semen quality parameters.
Results
Significantly greater PBMC proliferative responses specific to PAg, with elevated secretion of interferon (IFN)c and
interleukin (IL)-17, were detected in the patients with CP/CPPS vs the controls. Moreover, the patients with CP/CPPS had
significantly greater serum immunoglobulin G immune reactivity to SP proteins, such as prostate-specific antigen and
prostatic acid phosphatase, than the controls. Inflammation of the male genital tract was exemplified by high levels of IFNc,
IL-17, IL-1b and IL-8, as well as higher counts of leukocytes, mainly CD4 T lymphocytes and macrophages, in the semen.
In addition, this local inflammation was associated with an overall diminished semen quality, i.e., reduced sperm
concentration, motility and viability; and higher levels of sperm apoptosis/necrosis in patients with CP/CPPS vs controls.
Conclusion
Patients with CP/CPPS show T helper type 1 (Th1) and Th17 immune responses specific to PAg associated with chronic
inflammation of the male genital tract and reduced semen quality. These immune responses may underlie the induction
and development of chronic pelvic pain and inflammation of the male genital tract, which in turn could alter normal
prostate functioning and impair semen quality.
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Introduction
Prostatitis is a major medical problem, being the most
common urological diagnosis in men aged <50 years and the
third most common in older men [1]. Prostatitis is currently
classified into four categories by the National Institutes of
Health (NIH): acute bacterial prostatitis, chronic bacterial
prostatitis, chronic non-bacterial prostatitis/chronic pelvic
pain syndrome (CP/CPPS), and asymptomatic inflammatory
prostatitis [2]. CP/CPPS accounts for >90% of cases of
prostatitis and affects 8–14% of men of all ethnic origins
[3,4]. CP/CPPS has a considerable negative impact on quality
of life, similar to myocardial infarction, angina, or Crohn’s
disease [4]. It is a poorly understood clinical syndrome
characterised by local signs and symptoms of chronic
inflammation and genitourinary pain (defined as lasting ≥3 of
the preceding 6 months) in the absence of identifiable
urogenital infections [1]. As its aetiology remains obscure,
most therapies are empiric and ineffective [5]. CP/CPPS
appears to encompass similar clinical phenotypes resulting
from a wide array of heterogeneous conditions. It has been
suggested that dysregulated inflammation resulting from
autoimmunity against the prostate might be involved in its
onset and/or progression [6]. Indeed, no infectious cause has
been successfully identified to date and treatments with
corticosteroids or immunosuppressive drugs, rather than with
antibiotics, have been shown to be effective [5,7–9].
Moreover, the prostate-specific protein transglutaminase-4
(TGM4) has been identified as a target of the autoimmune
response in autoimmune polyendocrine syndrome type 1
(APS1), which presents with clinical and histopathological
prostatitis and subfertility in males [10]. Regarding the latter,
some recent evidence suggested that CP may have
andrological implications, as it could have deleterious effects
on semen quality compromising male fertility potential [11–
13]. Nonetheless, that issue remains controversial highlighting
the need for additional and compelling data [14].
In an effort to gain further understanding of the
pathophysiology underlying CP/CPPS, in the present study, we
analysed the presence of self-reactive immune responses to
seminal plasma (SP)-derived and prostate antigens (PAg),
inflammatory cytokines and leucocyte subpopulations in the
semen, and sperm quality parameters in patients with CP/CPPS.
Patients, Subjects and Methods
Patients and Subjects
CP/CPPS was defined as pain or discomfort in the perineum
and the suprapubic region with LUTS or sexual/ejaculatory
dysfunction, without infection [2]. Diagnosis was based on a
detailed history, physical examination, ultrasonography, and
laboratory evaluations. Inclusion criteria were men aged 18–
55 years with history of pain or discomfort in the prostate
region, painful DRE, negative Meares–Stamey test, no other
lower urinary tract pathology, and for ≥3 of the preceding
6 months a CP/CPPS history >1 year, and a NIH Chronic
Prostatitis Symptoms Index (NIH-CPSI) total score >15.
Control subjects had no history of any genitourinary
symptoms, instrumentation or surgery. Exclusion criteria
included specific disease-associated pelvic pain/discomfort
caused by non-CP/CPPS diseases (e.g. acute prostatitis,
bacterial prostatitis, BPH, prostate cancer, urogenital infection),
serious or acute disease of the heart, liver, kidney or blood,
vasectomy, toxic/pollutant exposure, any drug, alcohol or
marijuana consumption, antibiotic, steroids or NSAID
treatment during the preceding 12 weeks. Patients and controls
were prospectively included in the study and they donated
blood and semen samples. This study was carried out in
accordance with the Declaration of Helsinki and the
Argentinean legislation for protection of personal data (Law
25326). The experimental protocol was approved by the
Institutional Ethics Committee from the Hospital Privado de
Cordoba (Ref. #HP-4-132). All participants provided a signed
written informed consent prior to enrolment.
Lymphoproliferation Assays
Peripheral blood samples were obtained and collected in
sterile heparinised tubes. PBMC were purified by density
gradients (Ficoll-Paque PLUS, GE Healthcare Life Sciences,
Pittsburgh, PA, USA) and lymphoproliferation assays specific
to SP (SP0, human prostate homogenate (PHg), PSA and
prostatic acid phosphatase (PAP) were performed as
previously described [15]. In brief, PBMC were divided as
responder or antigen-presenting cells (APC). APC were
loaded with different PAg sources: dilutions (1:25) of pooled
SP from normal donors, PHg (100 µg/mL), PSA (10 µg/mL,
Sigma-Aldrich, St. Louis, MO, USA), PAP (10 µg/mL, Sigma-
Aldrich), or medium alone, and then irradiated at 3000 cGy.
Pulsed APC were added to plates containing 1.5 9 105
responder PBMC in quadruplicate and incubated for 96 h at
37 °C/5% CO2. Concanavalin A (5 µg/mL, Sigma-Aldrich)
was used as a positive control of proliferation. Supernatants
were collected and frozen at 80 °C for cytokine
quantification. DNA synthesis was measured by adding
37000 Bq of [methyl-3H] thymidine (Perkin Elmer, Waltham,
MA, USA) in fresh medium per well 18 h before harvesting
cells onto glass fibre filters. Labelled material was counted
and results expressed as a Proliferation Index (PI) calculated
from counts/min (cpm) incorporated in antigen-pulsed
cultures/cpm incorporated in cultures with medium. A PI of
≥2.00 was considered positive.
PAg-specific Antibodies in Serum
Immunoglobulin G (IgG) antibodies specific to SP, PSA or
PAP were assayed by conventional ELISA as previously
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described [15]. Serum reactivity was expressed as optical
density at 450 nm.
Semen analysis
Semen samples were obtained by masturbation after 4–7 days
of sexual abstinence and semen analysis performed according
to the WHO Semen Analysis Manual [16]. Semen analysis
was performed at least twice in each patient and control. The
sperm concentration and motility were evaluated soon after
liquefaction in a Makler chamber (Sefi-Medical Instrument,
Haifa, Israel) on a phase-contrast microscope. Sperm viability
and morphology were analysed using eosin Y (Sigma-Aldrich)
staining and the Papanicolaou technique, respectively. The
concentration of round cells was evaluated using the Makler
chamber and peroxidase-positive cells were quantified among
round cells using a cytochemical assay [17]. Semen citrate
and fructose concentrations were measured as biomarkers of
prostate and seminal vesicles function, respectively, by
colorimetric assays. Anti-sperm IgG antibodies were tested
using the direct SpermMAR test (FertiPro, N.V., Beernem,
Belgium). Routine sperm parameters were assessed in at least
200 spermatozoa/sample by two operators, rendering a total
of 400 scored spermatozoa.
Semen Leucocyte Analysis by Flow Cytometry
Leucocyte subpopulation analysis was performed in total
semen single-cell suspensions obtained after washing semen
aliquots with 10% fetal bovine serum, 2 mM EDTA, and
50 mM 2-mercaptoethanol supplemented Roswell Park
Memorial Institute (RPMI)-1640 medium. Cell suspensions
were stained with fluorescent-labelled antibodies to cluster
of differentiation (CD)45, CD3, CD4 and CD19
(BioLegend, San Diego, CA, USA), and to CD14
(eBioscience, San Diego, CA, USA). Cells were acquired
and analysed by fluorescence-activated cell sorting/flow
cytometry (FACS) on FACSCanto II cytometer
(BD Biosciences). A total of 100 000 cells/sample were
analysed.
Cytokine and PSA Quantification
Interferon (IFN)c, interleukin (IL)-10, IL-8, IL-17A and IL-1b
concentrations in SP or culture supernatants were analysed
using ELISA specific kits. IFNc, IL-10 and IL-8 were
respectively quantified by the BD OptEIATM Human IFNc, IL-
8 and IL-10 ELISA sets (BD Biosciences, cat. # 555142,
5126542 and 555157). IL-17A and IL-1b were respectively
assayed by the Human IL-17A ELISA Ready-SET-Go and
Human IL-1b ELISA Ready-SET-Go kits (eBioscience, cat. #
88-7010 and 88-7176). Serum PSA concentrations were
determined using chemiluminescence immunometric assay
kits (Immulite, Malvern, PA, USA).
Sperm apoptosis/necrosis
Sperm apoptosis/necrosis was assessed immediately after
semen liquefaction by annexin V/propidium iodide staining
and analysed by flow cytometry as previously described [18].
Statistics
Statistical analysis was performed using the Mann–Whitney
test. A P < 0.05 was considered statistically significant.
Compromise power analyses were calculated using G*Power3
data analysis software. Considering q: 0.5 and a: 0.05, the
statistical power of the study (1–b) was 0.68.
Results
Detection of PAg-specific T helper type 1 (Th1) and
Th17 immune responses in patients with CP/CPPS
To search for the presence of immune reactivity against PAg
in patients with CP/CPPS, we analysed peripheral blood
immune responses in the patients and controls. A total of 15
patients [mean (SD, range) age 40.3 (7.4, 30–55) years] and
10 controls [mean (SD, range) age: 37.7 (6.4, 24–45) years]
were included. As shown in Figure 1A, significantly greater
proliferative responses were detected when PBMC from
patients with CP/CPPS were in vitro stimulated with different
sources of PAg (SP or PHg) or purified PAg (PSA and PAP)
vs controls. Indeed, 53.3% (eight out of 15) of the patients
had positive lymphoproliferative responses to one or more of
the PAg assayed. Moreover, when assaying PAg-specific
cytokine secretion in culture supernatants, higher levels of
specific IFNc and IL-17 secretion to one or more of the PAg
assayed were detected in cell cultures from the patients with
CP/CPPS compared with the controls (Figure 1B).
Conversely, lower levels of PSA- and PAP-specific IL-10
secretion were observed (Figure 1B). On the other hand,
patients with CP/CPPS had higher serum levels of SP-, PSA-,
and PAP-specific IgG autoantibodies than the controls
(Figure 1C). Also, significantly higher levels of serum PSA
were found in patients with CP/CPPS than in the controls,
suggesting a state of inflammation of the prostate
(Figure 1D). These results indicate that patients with CP/
CPPS have Th1 and Th17 self-reactive immune responses
and also autoantibodies specific to PAg.
Patients With CP/CPPS Show Local Inflammation in
the Male Genital Tract
As shown in Figure 2A, flow cytometry analysis of semen
samples revealed that the patients with CP/CPPS had
significantly more leucocyte s in their semen when compared
with the controls. When analysing leucocyte subpopulations,
macrophages and CD4+ T helper cells were the most
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prominent cell subsets. Moreover, significantly higher levels of
inflammatory cytokines, such as IFNc, IL-17, IL-1b and IL-8,
were detected in the SP from patients with CP/CPPS
compared with the controls (Figure 2B). These results
indicate a state of chronic inflammation in the male genital
tract of patients with CP/CPPS, probably due to PAg-reactive
immune responses.
Patients With CP/CPPS Have Decreased Semen
Quality
To analyse if local male genital tract inflammation was
associated with diminished semen quality, we performed
semen analysis in the patients and controls. No significant
alterations in semen volume, pH values, fructose levels and
peroxidase-positive cell concentrations were found in the
patients with CP/CPPS compared with the controls.
Moreover, no presence of anti-sperm antibodies was observed
in either the patients or controls (Table 1). Conversely,
significantly lower seminal citrate levels were detected in the
patients than in the controls (Table 1). These data indicate
that the inflammatory milieu in the urogenital tract in
patients with CP/CPPS might impair prostate physiology.
Sperm quality parameters analysis showed significantly lower
sperm concentration, motility and viability, and higher counts
of round cells in the patients with CP/CPPS vs controls
(Table 1). Indeed, when sperm apoptosis/necrosis was



































































































































































Fig. 1 Self-reactive Th1 and Th17 immune responses specific to PAg in patients with CP/CPPS. (A) Lymphoproliferative responses of PBMC from patients
with CP/CPPS and age-matched control subjects to different SP-derived and PAg: dilutions (1:25) of SP obtained from pooled donor samples having a
normal semen analysis, PHg, PSA, PAP, or medium alone. Lymphoproliferative responses were expressed as PI calculated from counts/min (cpm)
incorporated in antigen-pulsed cultures/cpm incorporated in cultures with medium. (B) INFc, IL-17 and -10 secretion of PBMC from patients with CP/
CPPS and age-matched control subjects cultured with the same PAg sources assayed by sandwich ELISA. (C) Serum levels of IgG antibodies specific to
SP, PSA and PAP in patients with CP/CPPS and age-matched control subjects examined by indirect ELISA in 1:50 serum dilutions. Serum reactivity was
expressed as optical density (OD) at 450 nm. (D) Serum levels of PSA in patients with CP/CPPS and age-matched control subjects assayed by
chemiluminescence immunoassays and results expressed as ng/mL. Experiments were performed at least in triplicate and repeated twice with similar
results. Data are shown as mean  SD; patients with CP/CPPS, n = 15; age-matched control subjects, n = 10. Mann–Whitney test; *P < 0.05, **P < 0.01
and ***P < 0.005.
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higher levels of early apoptotic and late apoptotic/necrotic
spermatozoa were found in the patients vs controls
(Figure 3).
Overall, these results indicate that patients with CP/CPPS
show Th1- and Th17-associated self-immune responses
specific to PAg and higher levels of inflammatory cytokines
and leucocytes in their semen. Thus, the patients had local
inflammation with lower levels of biomarkers of prostate
physiology and reduced semen quality.
Discussion
Although CP/CPPS is the most common type of prostatitis
and genitourinary problem in adult males aged <50 years, it
is still an enigmatic disease mostly due to its uncertain
aetiology. That makes its diagnosis of exclusion, inadequate
and cumbersome. Moreover, therapies are empirical and
results ineffective for most patients [5]. Over the past decade,










































































































































































Fig. 2 Evidence of local inflammation in the male genital tract of patients with CP/CPPS. (A) Frequencies of leucocyte and different leucocyte cell
subsets in semen samples from patients with CP/CPPS and age-matched control subjects. Total leucocytes (CD45+), T lymphocytes (CD3+), helper T
lymphocytes (CD3+ CD4+), cytotoxic T lymphocytes (CD3+ CD4–), macrophages (CD14+) and B lymphocytes (CD19+) were assayed in semen samples
by flow cytometry. Analyses were performed in gates on the total leucocyte cell population (CD45+) using forward side scatter (FSC) vs CD45 dot plots.
A total of 100 000 cells/events per specimen were analysed. Results were expressed as % of cells. (B) INFc, IL-17, IL-1b and IL-8 levels in SP samples from
patients with CP/CPPS and age-matched control subjects assayed by sandwich ELISA. Experiments were performed in triplicate and repeated three-
times with similar results. Data are shown as mean  SD; patients with CP/CPPS, n = 15; age-matched control subjects, n = 10. Mann–Whitney test;
*P < 0.05 and **P < 0.01.
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pathogenic mechanism in CP/CPPS [6]. Prostate biopsies
revealed chronic inflammation in a considerable proportion
of patients and histological prostatitis was associated with a
shorter time to symptom progression [19,20]. Schwartz et al.
[21] reported that prostate inflammation significantly
increased urinary voiding frequency, induced hypersensitivity
to bladder distention, and sensitised bladder nerve afferents,
indicating cross-organ sensitisation and explaining the urinary
symptoms features of CP/CPPS. Although cryptic or difficult-
to-culture micro-organisms have been suggested as putative
causative factors, studies have systematically failed to identify
infectious agents as causative of this syndrome [22].
Moreover, most patients’ symptoms are refractory to
antibiotic monotherapy [9]. Nonetheless, if not pathogenic,
infections could be the initiating factor of dysregulated
inflammation in the form of autoimmunity [23]. An
autoimmune basis for CP/CPPS is a prominent theory based
on evidence obtained from studies in patients and animal
models [6,24]. Such animal models mirror most features of
human CP/CPPS and have shown that prostate inflammation
induction is mediated by T-cell responses specific to PAg. In
addition, they have shown that prostate inflammation induces
chronic pelvic pain development and has deleterious effects
on semen quality compromising male fertility [6,25].
However, compelling available data from studies in patients
are limited [6,25,26]. In the present study, we provide novel
evidence indicating that Th1 and Th17 self-reactive immune
responses specific to PAg are detected in a considerable
proportion of patients with CP/CPPS, which may be
responsible for the observed inflammation of the male genital
tract. Significantly increased lymphoproliferative responses
Table 1 Semen analysis in patients with CP/CPPS
Variable, mean (SD) Controls Patients P
Demographics
Age, years 37.7 (6.4) 40.3 (7.4) 0.540
Abstinence, days 4.6 (3.2) 5.4 (2.4) 0.411
Semen analysis
Volume, mL 3.2 (1.2) 4.1 (2.0) 0.438
pH 7.7 (0.1) 7.6 (0.2) 0.302
Concentration, 9106/mL 136.3 (84.6) 57.0 (58.0) 0.040
Total motility, % 65.2 (12.2) 43.1 (19.4) 0.043
Normal morphology, % 10.3 (6.4) 7.1 (3.5) 0.303
Viability, % 89.5 (5.6) 82.1 (5.9) 0.034
Round cells, 9106/mL 0.48 (0.28) 1.58 (0.91) 0.012
Peroxidase (+) cells, 9106/mL 0.19 (0.23) 0.81 (1.16) 0.386
Citrate, mg/dL 402.9 (54.1) 319.4 (98.1) 0.026
Fructose, mg/dL 349.9 (109.5) 334.2 (134.3) 0.971
Anti-sperm antibodies (ASA)*
IgG, % sperm agglutination 0.67 (0.81) 1.64 (5.10) 0.260
Mann–Whitney test; bolded values indicate statistical significance (P < 0.05).









































































































Fig. 3 Patients with CP/CPPS show increased levels of sperm apoptosis/necrosis. Sperm apoptosis/necrosis was evaluated by annexin V (AV)/
propidium iodide (PI) staining and FACS. Frequencies of live (AV, PI), early apoptotic (AV+/PI), late apoptotic/early necrotic (AV+/PI+) and late
necrotic (AV/PI+) spermatozoa in semen from patients with CP/CPPS and age-matched control subjects. Left, representative dot plots showing the
different labelling patterns in the bivariate PI-AV analysis that identified the different cell populations designated as viable, early apoptotic cells, late
apoptotic cells/early necrotic, and necrotic cells. Results are expressed as % of cells/100 000 events. Experiments were performed at least in triplicate
and repeated three-times with similar results. Data are shown as mean  SD; patients with CP/CPPS, n = 15; age-matched control subjects, n = 10.
Mann–Whitney test; *P < 0.05 and ***P < 0.005.
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were seen in patients when their PBMC were in vitro
stimulated with different SP-derived or purified PAg.
Moreover, increased levels of PAg-specific IFNc and/or IL-17
secretion were associated with these responses indicating a
Th1/Th17 mixed immune phenotype. In addition, these PAg-
reactive immune responses were concomitant with the
presence of local inflammation of the urogenital tract
evidenced by more macrophages/monocytes and CD4+ T
lymphocytes, high levels of IFNc, IL-17, and other pro-
inflammatory cytokines, such as IL-1b and IL-8, in the
semen. Moreover, these patients had low seminal levels of
citric acid, indicative of prostate dysfunction, and alterations
in sperm quality such as low sperm concentration, motility,
and viability, and higher levels of sperm apoptosis/necrosis.
Our present results are in agreement with the scarce reported
data [27,28]. Indeed, Kouiavskaia et al. [29] showed that
patients with CP/CPPS have increased frequencies of CD4+ T
cells specific to PAP. Moreover, it has been recently reported
that 30% of patients with IgG4-related disease have
symptoms of CP/CPPS and histopathological and
immunohistochemical evidence of prostatitis, which improve
after treatment with corticosteroids or immunosuppressive
drugs [7]. Noteworthy, these patients typically develop
autoimmune pancreatitis [7]. Also, Lu et al. [30] reported
that a significant proportion of patients with CP/CPPS have
autoantibodies against different immunodominant prostate
proteins, which were able to induce autoimmune prostatitis in
mice upon immunisation. Besides, and as mentioned above,
most patients with APS1 present elevated serum levels of
autoantibodies to TGM4, indicating that prostate
autoimmunity is a feature of APS1 that could also be
involved in male subfertility [10]. Chronic inflammation in
the form of autoimmunity develops when there is continuous
and uncontrolled induction and activation of the immune
response to self-antigens, which then causes persistent injury
and tissue damage. As the inflammatory process is not
interrupted, the production of inflammatory mediators such
as cytokines, chemokines and reactive oxygen species persists.
Autoimmune inflammation is sustained due to persistent
expression of self-antigens and by the lack of efficient control
by regulatory immune cell populations (e.g. regulatory T
cells), which usually bias the immune response to a
destructive Th1/Th17 phenotype. In particular, Th1 cells
secrete IFNc, a cytokine that causes activation of
macrophages, which have a dominant role in chronic
inflammation, as they contribute by secreting cytokines and
growth factors, such as IL-1b, IL-8, IL-23 and IL-12, further
enhancing inflammation by activating other cells, in
particular T cells [31]. In fact, Th1 and Th17 cells are known
to drive the pathogenesis of many autoimmune diseases [32].
In addition, IL-17 has been shown to be involved in
inflammatory and neuropathic pain induction [33].
Neurogenic processes, immune injury and inflammatory
mediators have been proposed to trigger pain development in
CP/CPPS [6,25]. In that regard, Th1 cells driving prostate
inflammation have been shown to mediate prostate
inflammation induction and chronic pelvic pain development
in an animal model of CP/CPPS [18]. In addition, Roman
et al. [34] recently showed that prostate inflammation induces
neuropathic changes and chronic pelvic pain through the
non-selective cation channel transient receptor potential
vanilloid 1 (TRPV1). Remarkably, IL-17 has also been
postulated to play a key role in the induction of chronic
pelvic pain in another animal model of CP/CPPS [35]. Our
present results revealed the presence of Th1 and Th17
immune responses specific to PAg and increased SP levels of
IFNc and IL-17 in patients with CP/CPPS. Altogether, this
evidence further supports the notion that IFNc and IL-17
may be involved in the onset and progression of
inflammation and chronic pelvic pain development in CP/
CPPS.
The prostate is the major male accessory gland and
secretes several factors that exert crucial functions for
human reproduction [25,36]. Therefore, it is reasonable to
hypothesise that inflammation of the prostate could alter
male fertility potential [36]. In fact, prostatitis has been
postulated as a potential risk factor for male infertility
[11,25]. However, the impact of prostatitis on semen
quality remains controversial, as conflicting results have
been reported [36]. Although some reports have shown a
negative impact of CP/PPS on sperm quality [37–39], other
studies did not reveal any difference in sperm quality
parameters between patients with CP/CPPS and controls
[40,41]. Our present results showed that patients with CP/
CPPS had increased levels of macrophages, T lymphocytes
and inflammatory cytokines in their semen, and alterations
in semen quality parameters. Flow cytometry analysis
revealed increased levels of leucocytes, mostly macrophages
and T lymphocytes, in the semen from patients with CP/
CPPS. However, cytochemical analysis of those semen
samples revealed no increases in peroxidase-positive cells.
These results highlight the need to properly interpret
negative results when assaying leucocytes in semen by the
peroxidase assay, as it mainly identifies neutrophils but no
other leucocyte subsets. In addition, patients with CP/CPPS
had sperm quality alterations such as lower sperm
concentration, motility and viability associated with elevated
levels of IFNc, IL-17, IL-1b and IL-8, and more sperm
apoptosis/necrosis. Cytokines such as tumour necrosis factor
a, IL-1b, IL-6, and IL-8 have already been reported to be
elevated in patients with CP/CPPS [42–44]. Moreover, IL-6
and IL-8 have been proposed as biomarkers of urogenital
inflammation [45–47]. Nonetheless, and to the best of our
knowledge, we report for the first time elevated levels of
IL-17 and IFNc in urogenital secretions from patients with
CP/CPPS [42].
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Although our present results are consistent with cumulative
reported evidence, they should be interpreted with caution, as
the statistical power of the study is limited. Additional studies
including larger patient populations are needed to further
support our present data.
In conclusion, our present results provide novel evidence
indicating that patients with CP/CPPS show Th1 and Th17
self-reactive immune responses to PAg, associated with
inflammation of the male genital tract and reduced semen
quality. Our present results suggest that dysregulated
inflammation in the form of autoimmunity may underlie the
induction and development of chronic pelvic pain and
inflammation of the male genital tract in CP/CPPS.
Moreover, the local inflammatory milieu could alter normal
prostate functioning and impair semen quality, thus
compromising male fertility potential.
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